rs35478150
Positions:
Variant summary
Our verdict is Benign. Variant got -20 ACMG points: 0P and 20B. BP4_StrongBP6_Very_StrongBA1
The NM_001323289.2(CDKL5):āc.2372A>Cā(p.Gln791Pro) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.0439 in 1,127,311 control chromosomes in the GnomAD database, including 931 homozygotes. There are 14,285 hemizygotes in GnomAD. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Benign (ā ā ).
Frequency
Genomes: š 0.032 ( 65 hom., 938 hem., cov: 23)
Exomes š: 0.045 ( 866 hom. 13347 hem. )
Consequence
CDKL5
NM_001323289.2 missense
NM_001323289.2 missense
Scores
2
7
7
Clinical Significance
Conservation
PhyloP100: 7.36
Genes affected
CDKL5 (HGNC:11411): (cyclin dependent kinase like 5) This gene is a member of Ser/Thr protein kinase family and encodes a phosphorylated protein with protein kinase activity. Mutations in this gene have been associated with X-linked infantile spasm syndrome (ISSX), also known as X-linked West syndrome, and Rett syndrome (RTT). Alternate transcriptional splice variants have been characterized. [provided by RefSeq, Jul 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Benign. Variant got -20 ACMG points.
BP4
Computational evidence support a benign effect (MetaRNN=0.007584989).
BP6
Variant X-18619962-A-C is Benign according to our data. Variant chrX-18619962-A-C is described in ClinVar as [Benign]. Clinvar id is 136713.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chrX-18619962-A-C is described in Lovd as [Benign].
BA1
GnomAdExome4 highest subpopulation (NFE) allele frequency at 95% confidence interval = 0.0523 is higher than 0.05.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
CDKL5 | NM_001323289.2 | c.2372A>C | p.Gln791Pro | missense_variant | 16/18 | ENST00000623535.2 | NP_001310218.1 | |
CDKL5 | NM_001037343.2 | c.2372A>C | p.Gln791Pro | missense_variant | 17/22 | NP_001032420.1 | ||
CDKL5 | NM_003159.3 | c.2372A>C | p.Gln791Pro | missense_variant | 16/21 | NP_003150.1 |
Ensembl
Frequencies
GnomAD3 genomes AF: 0.0320 AC: 3600AN: 112544Hom.: 65 Cov.: 23 AF XY: 0.0270 AC XY: 938AN XY: 34680
GnomAD3 genomes
AF:
AC:
3600
AN:
112544
Hom.:
Cov.:
23
AF XY:
AC XY:
938
AN XY:
34680
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0313 AC: 5337AN: 170666Hom.: 97 AF XY: 0.0311 AC XY: 1792AN XY: 57712
GnomAD3 exomes
AF:
AC:
5337
AN:
170666
Hom.:
AF XY:
AC XY:
1792
AN XY:
57712
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0452 AC: 45855AN: 1014712Hom.: 866 Cov.: 22 AF XY: 0.0448 AC XY: 13347AN XY: 298150
GnomAD4 exome
AF:
AC:
45855
AN:
1014712
Hom.:
Cov.:
22
AF XY:
AC XY:
13347
AN XY:
298150
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0320 AC: 3602AN: 112599Hom.: 65 Cov.: 23 AF XY: 0.0270 AC XY: 938AN XY: 34745
GnomAD4 genome
AF:
AC:
3602
AN:
112599
Hom.:
Cov.:
23
AF XY:
AC XY:
938
AN XY:
34745
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
TwinsUK
AF:
AC:
200
ALSPAC
AF:
AC:
142
ESP6500AA
AF:
AC:
22
ESP6500EA
AF:
AC:
326
ExAC
AF:
AC:
3881
ClinVar
Significance: Benign
Submissions summary: Benign:13
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not specified Benign:8
Benign, criteria provided, single submitter | clinical testing | GeneDx | Mar 23, 2012 | This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. - |
Benign, no assertion criteria provided | clinical testing | Genomic Diagnostic Laboratory, Division of Genomic Diagnostics, Children's Hospital of Philadelphia | Feb 13, 2015 | - - |
Benign, no assertion criteria provided | clinical testing | Joint Genome Diagnostic Labs from Nijmegen and Maastricht, Radboudumc and MUMC+ | - | - - |
Benign, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | Aug 20, 2015 | - - |
Benign, no assertion criteria provided | curation | RettBASE | May 15, 2014 | Common polymorphism - |
Benign, criteria provided, single submitter | clinical testing | PreventionGenetics, part of Exact Sciences | - | - - |
Benign, criteria provided, single submitter | clinical testing | Genetic Services Laboratory, University of Chicago | Feb 08, 2013 | - - |
Benign, no assertion criteria provided | clinical testing | Genome Diagnostics Laboratory, University Medical Center Utrecht | - | - - |
Developmental and epileptic encephalopathy, 2 Benign:1
Benign, criteria provided, single submitter | clinical testing | Genome-Nilou Lab | Jul 22, 2021 | - - |
CDKL5 disorder Benign:1
Benign, criteria provided, single submitter | curation | Centre for Population Genomics, CPG | Sep 16, 2024 | This variant has been collected from RettBASE and curated to current modified ACMG/AMP criteria. Based on the classification scheme defined by the ClinGen Rett/Angelman-like Expert Panel for Rett/AS-like Disorders Specifications to the ACMG/AMP Variant Interpretation Guidelines VCEP 3.0, this variant is classified as benign. At least the following criteria are met: The allele frequency of this variant in at least one population in gnomAD is higher than the 0.03% threshold defined by the ClinGen Rett/Angelman-like Expert Panel for Rett/AS-like Disorders VCEP 3.0 (BA1). - |
not provided Benign:1
Benign, criteria provided, single submitter | not provided | Breakthrough Genomics, Breakthrough Genomics | - | - - |
History of neurodevelopmental disorder Benign:1
Benign, criteria provided, single submitter | clinical testing | Ambry Genetics | Jun 25, 2015 | This alteration is classified as benign based on a combination of the following: population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. - |
Developmental and epileptic encephalopathy, 2;CN128785:Angelman syndrome-like Benign:1
Benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Feb 01, 2024 | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
BayesDel_addAF
Benign
T
BayesDel_noAF
Benign
CADD
Uncertain
DANN
Uncertain
DEOGEN2
Benign
T;T;T;.
FATHMM_MKL
Pathogenic
D
LIST_S2
Uncertain
.;D;D;D
MetaRNN
Benign
T;T;T;T
MetaSVM
Uncertain
T
MutationAssessor
Uncertain
M;.;M;M
PrimateAI
Uncertain
T
PROVEAN
Benign
N;.;N;.
REVEL
Uncertain
Sift
Pathogenic
D;.;D;.
Sift4G
Uncertain
D;.;D;D
Polyphen
D;.;D;.
Vest4
MPC
0.52
ClinPred
T
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at